Septerna (NASDAQ:SEPN – Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.
Septerna Stock Performance
Shares of Septerna stock opened at $11.38 on Wednesday. The stock has a fifty day moving average price of $20.17. Septerna has a 12-month low of $11.27 and a 12-month high of $28.99.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on SEPN. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a report on Tuesday. Wells Fargo & Company began coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
- Five stocks we like better than Septerna
- How to invest in marijuana stocks in 7 steps
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Bank Stocks – Best Bank Stocks to Invest In
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.